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Abstract 
Non-alcoholic fatty liver disease (NAFLD) is clearly shown hepatic metabolic syndrome. It represents 
histopathological abnormalities which range from simple steatosis to non-alcoholic steatohepatitis (NASH) which 
eventually leads to fibrosis then cirrhosis and hepatocellular carcinoma. The buildup of toxic free fatty acids and 
mobilization of free fatty acid from adipose tissue and de novo hepatic fatty acid synthesis from glucose is denoted 
at the “first-hit”for NAFLD development. NAFLD progression leads to ‘parallel, multiple fit’ injuries such as 
oxidative-stress-induced mitochondrial dysfunction, ER stress, TLR-4 dependent release of inflammatory cytokines, 
these deleterious factors trigger the number of the signalling cascade that leads to inflammation, cell death& 
fibrosis, these are the hallmarks of NASH. It is such a chronic liver disease that leads to liver cirrhosis,liver cancer 
& ultimate death. This review identifies NAFLD progression and development screening method allows clinicians 
to isolate high-risk NAFLD patients that require early intensive intervention. 
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Introduction 
 
Long chain fatty acids are a major source of energy and 
a necessary component of membrane lipids. They can 
be derived from food and synthesized from acetyl Co-
A through a complex set of reactions, including 
glycolysis and TCA cycle, which together lead to the 
formation of backbone carbon of fatty acid and 
alongwith glycerols for the synthesis of lipids [1].The 
synthesis of fatty acid by FAS (Fatty Acid Synthase) 
requires NADPH, acetyl Co-A and malonyl Co-A. 
Malonyl Co-A is the carbon donor and help in the 
denovo synthesis of fatty acid and plays an important 
role as an inhibitor of CPTI (Carnitine/palmitoyl 
shuttle system) for fatty acid oxidation [2]. 
Survival of animals requires the availability of food 
Sources, in nature, the quality and quantity are highly 
variable. Once the animal locates the right meal, they 
eat as much as possible because they do not know 
when they will have the next, and survive.  
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As animals consume the meals of carbohydrates, 
proteins and fats, through digestion, absorption and 
assimilation glucose, amino acid and fatty acid 
respectively are generated. Their metabolites provide 
the substrate for immediate energy needs in the form of 
glycogen, muscle protein and fats. When food is not 
available these stored glycogens, muscle proteins and 
fats get mobilized, degraded and consumed within a 
few days. Fat stores provide energy for longer times, in 
human 60 days, in polar bears for 6 months and in 
migratory birds for flying thousands of miles.For 
animals to exist for such a longer period of starvation, 
they needed synthesis and saving of the acquired fat 
and this special mechanism involve ACC1, ACC2 and 
CPTI. 
Non-alcoholic fatty liver disease (NAFLD) is a 
different type of liver disease which is not affected by 
alcohol intake. It is caused by the high level of 
accumulated fat in the liver. Our normal liver is about 
5-10% fat. It is defined as a clinicopathological 
syndrome which cannot be explained by excessive 
alcohol consumption. It was unidentified until the 
1980s, but now it is recognized as the most common 
chronic liver disease in most parts of the world and 
western countries are in the first position. The disease 
increased its prevalence worldwide ranges from 6 to 
35% in the general population from different countries. 
This high variability is due to differences in patients 
selection, diagnostic methods and dietary/lifestyle 
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customs. In the last 20 years, NAFLD among chronic 
liver disease increased from 47 to 75%.This high 
prevalence leads to NAFLD to become the leading 
cause of end-stage liver disease, liver transplantation 
and HCC(hepatocellular carcinoma) over the next 
decade. A reason for the high prevalence of NAFLD is 
that it is strongly linked to obesity, which is the global 
epidemic mainly associated with hypercaloric diet and 
low physical activity. Non-alcoholic fatty liver disease 
is the main hepatic manifestation of metabolic 
syndrome. It represents wide histopathological 
abnormalities ranging from simple steatosis to non-
alcoholic steatohepatitis (NASH)[3].The progression of 
the disease is explained two decades ago by Day et al. 
by the “two-hit hypothesis”. 
The ‘first hit’ is by the lipid accumulation in the 
hepatocyte, a trait in which fat intake and IR (Insulin 
Resistance) play a key role. This condition enhances 
the vulnerability of the liver for damaging factors and 
this gives rise to ‘second hit’, for example, oxidative 
stress(OS),increased susceptibility  to the disease, 
release of pro-inflammatory cytokines cause activation 
of inflammatory pathways by kupffer cells, adipokines 
from adipocyte, dysregulated hepatocyte apoptosis 
activation of hepatic stellate cells (HSC). This all 
constitutes the ‘second hit’ which when acts separately 
leading to macrovesicular steatosis to NASH [3].This 
progression leads to liver injury which associates 
hepatocyte apoptosis, liver inflammation, fibrogenesis, 
cirrhotic remodelling with liver failure and finally 
hepatocarcinogenesis. 
Physiopathological and Histological Mechanism of 
NAFLD 
NAFLD has a wide histological spectrum, in this pure 
triglyceride accumulate in droplets in the hepatocytes. 
If the inflammation occurs with or without fibrosis then 
it reaches to its next stage, a disorder referred to as 
NASH, this may eventually evolve to cirrhosis and 
hepatocellular carcinoma. The patients with early stage 
of NASH may progress to cirrhosis over a period of 5-
10 years [4],and some may develop HCC. This is the 
chance that HCC may arise without cirrhosis[5, 6]. 
By the time after second hit theory, the concept has 
evolved and the progression of the disease explained 
more perfectly by a ‘parallel multiple hit theory’. 
According to this theory, IR is an independent risk 
factor for NAFLD, it would be the ‘first hit’ that 
triggers the disease which leads to hepatocellular 
elevation of free fatty acids (FFAs),this molecule 
considered as the main pathogenic factor that makes 
the liver vulnerable for the above stated further hits. 
According to this model NASH as a condition which is 
preceded by IR (from a pathophysiological point of 
view) and by simple, macrovesicular steatosis (from a 
histological point of view). 
Now,a more recent ‘distinct-hit theory’ has emerged 
which states the NASH and pure fatty liver are two 
independent twin conditions that are caused by IR, with 
steatosis in NASH is the beginning of epiphenomenon 
rather than a causal factor for inflammation and 
fibrosis, these are the two hallmarks for NASH[7]. 
Metabolic basis of pathogenesis: NAFLD 
Dietary fat is the primary supply of adipocyte FFAs 
which goes to the liver and re-esterified there [8]. IR, 
lipolysis of peripheral fat which mobilizes to the liver 
in the form FFA and exacerbated hepatic lipogenesis, is 
the most important factor involved in hepatic FFA 
accumulation.[8],[9]. In NAFLD patients 80%of the 
total circulating FFA pool contributed by circulating 
FFA derived from dysregulated lipolysis in adipose 
tissue. Most of the hepatic fat comes from this FFA 
pool (59%)and other fraction comes from de novo 
lipogenesis (26%)and the remaining 15 % from the diet 
[10]. 
Anyone who is obese has IR and we can say both type-
2 diabetes and obesity are interlinked with each other 
and are associated with IR. Obesity leads to chronically 
elevated FFAs in serum and IR can disturb different 
metabolic pathways and can induce IR in many tissues, 
like adipose one. Adipose tissue is the repository of 
excess energy derived from food intake and the unique 
physiological lipid depot. In obesity, there is massive 
accumulation of fat in adipose tissue that leads to 
dysfunctional adipocyte that causes abnormal release 
of adipokines[11], including inflammatory cytokines 
such as tumor necrosis factor-alpha(TNF-alpha), 
interleukin-6(IL-6), resistin, plasminogen activator and 
monocyte chemoattractant protein-1 (MCP-1) that 
impairs  adipocyte response to insulin [12]; [13]. 
Lipase, is the rate-limiting enzyme that catalyzes TG 
lipolysis in adipose tissue are inhibited by insulin 
(hormone sensitive to lipase),IR in this tissue leads to 
failure in the inhibition of the enzyme involved in 
adipocyte lipolysis[14].This leads to massive 
mobilization of FFAs from adipose tissue to other non-
adipose tissue and causes ectopic intracellular 
accumulation of FFAs. This fact with the distance 
action of cytokines {fat derived) leads to generalized 
IR [15].The liver receives an overload of glucose i.e. 
not internalized by peripheral tissues and insulin (due 
to compensatory hyperinsulinemia)when there is 
impairment of insulin uptake which is IR induced, 
predominates in extrahepatic tissue[16]. Under this 
condition, both glucose, through activation of the 
transcription factor carbohydrate response element 
binding protein (ChREBP) and insulin, through 
activation of the transcription factor sterol regulatory 
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binding protein-1c(SREBP-1c)induces the liver 
synthesis of FFAs [17]. 
SREBP-1c activates the transcription of the gene that 
codifies enzymeor transporters involved in FFA 
metabolism, FFA synthesis (e.g. ACC (acetyl-co-A 
Carboxylase and FFA synthase) and TG synthesis 
(e.g.glycerol-3-phosphate acyltransferase)[17, 18]. 
ChREBP also stimulates transcription of many 
lipogenic genes. It also induces the expression of liver-
type pyruvate kinase (L-PK),hasa key role in the 
regulation of glycolysis and glucose-6-phosphate 
(G6P),it is the critical enzyme that is involved in 
gluconeogenesis [17, 19-21].LXR(Liver X receptor) is 
the ligand-activated nuclear receptor, its activation 
leads to induction of SREBP -1C by dietary 
cholesterol. SREBP-1C is the transcription factor 
which binds to oxysterols, intermediate metabolites in 
the bile acid biosynthetic pathways from 
cholesterol[22].The kind of fatty acid we consume in 
our diet also impact on the SREBP-1C expression, 
saturated one upregulates while polyunsaturated ones 
down regulate the transcription factor [23]. Fructose 
intake also activates both SREBP-1C and ChREBP[24, 
25] 
Apolipoprotein(apo) B synthesis, the main protein 
cofactor of very low-density lipoprotein (VLDL) 
repressed by insulin and that resulting in impair 
exportation of hepatic lipid through this lipoprotein 
[26].Another impairment in the VLDL exportation is 
the shortage of the main human methyl donor, S-
adenosylmethionine (SAMe)[27, 28].In advanced 
NAFLD there is an impairment in mitochondrial β-
oxidation,in this metabolic process FFAs is converted 
into ketone bodies. This impairment is caused due to; 
SREBP-1C mediated induction of acetyl-co-A 
carboxylase2 (ACC2)which leads to the 
overproduction of malonyl-co-A, a metabolite 
inhibitory β-oxidation regulatory enzyme carnitine 
palmitoyltransferase1(CPT1)[29]. Accumulation of 
atypical toxic lipids in hepatocyte that inhibit 
mitochondrial β-oxidation, like oxidized cardiolipin 
[30, 31] and ceramides [32, 33]. 
The OS due to a metabolic process developed within 
mitochondria, it can damage complexes of the 
mitochondrial respiratory chain. This event eventually 
impairs β-oxidation, also hampers the re-oxidation of 
& FADH2into NAD+ and FAD,it leads to inhibition of 
mitochondrial β-oxidation andthe tricarboxylic acid 
cycle that requires NAD+ and FAD to occur [34].FFA 
β-oxidation in the later stages of NASH can be 
augmented and treated as a compensatory mechanism 
to the increased uptake and synthesis of FFAs [35], this 
involves both activations of PPAR-α(peroxisome 
proliferator-activated receptor-α),and consequent 
enhancement of CPT1activity and loss of affinity of 
CPT1 for its inhibitor, malonyl-CoA[36]. Other 
cellular FFAoxidation mechanism, including 
peroxisomes (β-oxidation) & microsomal (ω-
oxidation), are also upregulated to decrease FFA 
accumulation, with the former increase in the H2O2 
production in peroxisome [37]. However, these 
processes might not overcome the increasing rate of 
liver FFA synthesis. 
Concluding, in addition to extrahepatic IR, it is well 
recognized that IR at the hepatic level also plays a 
major role in NAFLD/NASH [38]. Because of 
impaired insulin degradation, NAFLD itself can 
promote hyperinsulinemia[39]. Excessive FFA 
accumulation in liver triggers pro-oxidizing, pro-
fibrotic,pro-inflammatory and pro-apoptotic signal 
pathwaythat leads to characteristic features of NASH 
i.e. OS, inflammation, fibrosis, and apoptosis.FFA 
accumulation may induce: OS, due to mitochondrial 
over function [40], and further mitochondrial 
dysfunction [36], as well as it leads to induction of 
cytochrome P450 family 2 subfamily E member 1 
(CYP2E1)[41, 42]. Systemic and hepatic inflammation, 
with upregulation of pro-inflammatory cytokines, such 
as TNF α and different interleukins, they are pro- 
steatotic, pro-inflammatory, profibrotic& pro-apoptotic 
in nature [43]. Production of TGF-β (transforming 
growth factor-β)by kupffer cells, that activates HSCs 
that produce collagen and it leads to fibrosis [44]. The 
upregulation of hepatocyte apoptosis via OS and 
cytokine-mediated mechanisms[45].All these events 
are intertwined and a vicious cycle occurs between 
them. 
Pathogenesis 
Disease development is complicated and has been 
designated as “multiple hit and organ theory”[46]. 
Mechanism of steatogenesis 
The initial step of NAFLD onset is the accumulation of 
triacylglycerol in hepatocytes. FA is usually absorbed 
from the circulation into the hepatocyte and other from 
glucose in the liver by the process of lipogenesis. FA β-
oxidation is mainly regulated by the nuclear receptor 
peroxisome proliferator-activated receptor-α (PPAR-
α).Its down-regulation leads to NAFLD/NASH. 
Hyperglycemia enhances de novo lipogenesis that is 
strongly regulated by insulin by activation of 
transcriptional factor sterol regulatory element binding 
protein-1c (SREBP-1c). This mechanism partially 
explains the very close relationship between 
NAFLD/NASH and IR (Insulin Resistance). The 
changes in hepatocyte lipid droplets are important 
considerations in the mechanism of hepatic steatosis. 
Approximately 60% of fatty acid originates in the liver 
from white adipose tissue[10], and its dysfunction will 
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lead to the FA overflow and resultant 
NAFLD/NASH.Humans having CIDEC mutation 
exhibit lipodystrophy, additionally, insulin resistance 
and it give rise to NASH with advanced fibrosis [47]. It 
has been diagnosed that adipocyte-specific FSP27 
disrupted mice because of impaired fat storage and due 
to enhanced lipolysis in white adipose tissue aggravate 
high-fat diet-induced hepatic steatosis[48]. This 
enhanced white adipose lipolysis induced by a choline-
deficient dietof steatotic mice promotes FA 
mobilization from adipose to liver that increases 
hepatic oxidative stress and that leads to the 
development of steatohepatitis. 
Mechanism of promoting hepatocyte injury and 
inflammation 
TAG  stored as lipids are not toxic to hepatocytes. 
TAG precursors and intermediates,like palmitate, DAG 
(diacylglycerol) and ceramide are causing harm to 
hepatocyte. Palmitate is responsible for oxidative stress 
and ER stress, leading to c-jun N–terminal kinase 
(JNK) activation and lipoapoptosis. [49-51]. 
Diacylglycerol activates protein kinase C and also 
leads to the disruption of insulin signalling. Ceramide 
is taking part in upregulation and expression of SREBP 
-1c and promotes the production of palmitate[52]. Fat 
rich cells are prone to lipid peroxidation, which leads 
to mitochondrial and ER dysfunction.If cholesterol is 
freely circulating it also causes mitochondrial 
dysfunction andinflammasome activation [53]. Injury 
in NASH is cytotoxicities andlipotoxicities mediated 
and it is the major cause. 
Diagnosis  
NAFLD is detected by abnormal liver function, often 
asymptomatic,imaging results in health checkups and 
can be detected during follow up for other diseases. 
Patients can be suspected having NAFLD with an 
elevation of serum aspartate aminotransferase (AST) & 
alanine aminotransferase(ALT) and fat change on 
ultrasonography (US) or computed tomography (CT) 
without having a history of habitual drug or ethanol 
intake or positive HBV or autoantibodies. 
NAFLD/NASH can also develop after gastrointestinal 
surgery,involving pancreaticoduodenectomy and 
intestinal bypass[54, 55]. 
Careful exclusion of some disorders like Wilson's 
disease, citrin deficiency[56-58] and cholesteryl esters 
storage disease[59]exhibits hepatic steatosis and it 
mimics NAFLD. In cirrhotic NASH, AST/ALT levels 
in serum and hepatic TAG accumulation in hepatocyte 
are markedly reduced, which may be diagnosed or 
cryptogenic liver cirrhosis[60, 61]) Hereby, should be 
noted that normal ALT levels cannot exclude the 
happening of NASH with advanced fibrosis, for an 
accurate  diagnosis combination of liver function 
testing with fibrosis markers should be done. 
Borderline between non-alcoholic &alcoholic status 
Because the impact of ethanol on the liver differs that’s 
why threshold of ethanol consumption between 
NAFLD and alcoholic liver disease is problematic as it 
differs among individual with regards to race, sex, 
aldehyde dehydrogenase 2 gene polymorphism, mode 
of drinking and lifestyle. It is hard to estimate the 
precise amount of ethanol intake. According to some 
reports have shown that mild drinking reduces hepatic 
steatosis.The occurrence rate of HCC is higher in those 
patients which had mild drinking habit (<20 g/d) 
having higher male prevalence, increased gamma-
glutamyltranspeptidase, and more frequent liver 
cirrhosis[62]. 
Evaluation of hepatic steatosis using imaging 
modalities 
Ultrasonography is a method to detect fatty liver, but 
its quantitative performance guidelines cause 
interobserver differences that complicate the 
monitoring of fat accumulation changes during 
interventions [63, 64].CT is calculated by Hounsfield 
unit (HU) abdominal CT liver/spleen scores of <40 or 
ratio of liver/spleen <0.9 indicates the presence of 
hepatic steatosis.As CT has greater quantitative 
performance, objectivity and reproducibility as 
compared with the US, it is having some disadvantages 
like radiation exposure, cost, HU variability which 
depends on device set-up and inaccuracy is iron/copper 
depositions [63, 64]. MRI (Magnetic Resonance 
Imaging) perfectly quantify the hepatic fat 
accumulation. 
CAP (Controlled Attenuation Parameter) and E value is 
quantified through recently introduced Fibroscan, it 
quantifies the degree of hepatic fat accumulation and 
fibrosis. CAP values are correlated with the area of 
lipid droplets in liver histology only in NAFLD 
patients having BMI < 28 kg/m2. Now, further 
improvements in diagnostic performance are needed in 
this area as there are large number of obese patients. 
Clinical Significance of Liver Biopsy and  Detection 
Of Ballooned Hepatocytes 
Repeated liver biopsy is somewhat invasive, costly and 
ultimately unrealistic. There is a problem in sampling 
error and its diagnosis[65-67].In order to search for less 
invasive and more accurate methods to asses NAFLD 
pathology, several serum biomarkers have been 
detected to see the presence of ballooned 
hepatocytes[68-72]. For example, cytokeratin 18 (CK 
18) accumulates with Mallory-Denk body-like 
inclusion bodies. CK18 circulating fragment is 
significantly increased in NASH  compared to 
NAFLD. Prognosis of NASH is poorer than NAFLD. 
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NASH is steatosis without ballooned hepatocytes. 
NASH may transform into NAFLD as ballooned 
hepatocytes may sometimes disappear and vice versa. 
NAFLD is not always benign as it is described by one 
case, one patient with  NAFLD at first liver biopsy 
gradually preferred to cirrhosis and HCC over 20 years 
and he underwent careful for 27 years follow up [60]. 
HCC may develop from NAFLD regardless of the 
absence of advanced fibrosis, past HBV infection, or 
regular ethanol consumption [73].Recent studies have 
detected the presence of advanced fibrosis, but not 
ballooned hepatocytes, was a clear picture of poor 
prognosis in NAFLD patients.If we take all together, it 
seems that the clinical significance of ballooned 
hepatocytes has given the way to that of fibrosis in 
NAFLD/NASH. 
Evaluation of liver fibrosis 
Platelet count and serum levels of hyaluronic acid, 
Mac2-binding protein, autotoxin, type 4 collagen 7S 
are relevant biomarkers that predict advanced fibrosis 
(Table 1)[74-78]. Results are emphasised by some 
conditions like co-existing collagen disease, systemic 
inflammation and renal dysfunction. AST-to- platelet 
ratio index (APRI), NAFLD fibrosis score, FIB-4 
index, BARD, CA index ELF, and fibro test have 
indicators to predict advanced fibrosis in NAFLD 
patients (Table 2)[79-82]. 
Fibrotest and ELF are direct markers of collagen 
synthesis & degradation, but these measurements are 
not common in clinical situations.These test like 
NAFLD fibrosis score, APRI and FIB-4 exploit the 
biochemical test components of age, ALT, 
AST,glucose,BMI, platelets and albumin, they are 
routinely obtained in clinical practice. This is also 
unclear that changes in AST, ALT and BMI are 
correlated with the degree of actual fibrosis. 
 
Table 1:Biomarkers predicting ≥ F3 fibrosis in Japanese non-alcoholic fatty liver disease patients 
Biomarker  Fibrosis stage Cut-off value          AUC Reference 
Platelet count F4 15.3×104/µL 0.92 [74] 
 F4 16×104/µL 0.98 [75] 
Hyaluronic acid ≥F3 42ng/mL 0.97 [75] 
Type 4 collagen 7S ≥F3 6.0ng/mL 0.88 [76] 
Mac2-binding 
protein 
≥F3 2.24 µg/mL 0.78 [83] 
WFA+ Mac2-
binding protein 
≥F3 1.23 COI 0.83 [77] 
Autotaxin ≥F3 1.19mg/L 0.75 [78] 
 F4 1.20mg/L o.87  
AUC: Area under the receiver operating characteristic curve 
Table 2.Representative indices predicting ≥F3 fibrosis in non-alcoholic fatty liver disease patients 
Score/index Formula  Reference 
NAFLD Fibrosis curve 1.675+0.037×age +0.094×BMI 
+1.13X IFG/DM (with 
=1,without=0)+0.99×AST/ALT-
0.013×PLT-0.66×Alb 
[78] 
APRI [(AST/upper limit of normal AST) 
PLT]×100 
[80] 
FIB-4 Index [age×AST]/[PLT×ALT1/2] [81] 
BARD score BMI≥28(1 point) AST/ALT≥0.8(2 
point) 
The presence of DM (1 point) 
[82] 
ELF score 2.494 + ln (hyaluronic acid)+In (P-
III-P)+In(TIMP-1) 
[84] 
CA index –fibrosis 1.5 ×4C7S + 0.0264×AST [85] 
 
BMI-Body Mass Index; IFG: Impaired Fasting Glucose;ALT: Alanine aminotransferase; AST: Aspartate 
aminotransferase; PLT: Platelet count; Alb:Albumin; 4C7S:Type 4 collagen 7S; P-III-P:Procollagen  type III amino-
terminal peptide;TIMP-1: tissue inhibitor of metalloproteinase-1;NAFLD: Non-alcoholic fatty liver disease. 
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Treatment  
Treatment from liver fibrosis is body weight reduction. 
Body weight Reduction 
The early stage of NAFLD/ NASH is resolved by 
weight loss, lifestyle modifications that will reduce 
weight are routinely prescribed. NASH patients who 
received repeated biopsy and having weight loss, 
absence of diabetes, ALT normalization, young age & 
baseline NAS <5 are predictions for NASH resolution 
without fibrosis after 1 year of lifestyle management 
(Vilar Gomez et al ([86]. Multi-disciplinary 
cooperation of doctors (gastroenterologist, cardiologist, 
endocrinologist etc.), nurses, dietitians and exercise 
therapist are needed for facilitating the exercise 
regimens to achieve 10% weight loss. For unsuccessful 
weight reduction for morbid obesity, bariatric surgery 
is a promising option. It is proven that bariatric surgery 
can significantly improve NASH [87]. It gives long 
term safety and its effectiveness is always under 
debate. 
Pharmacological interventions for underlying 
disorders:- 
NAFLD/NASH diseases are accompanied by 
dyslipidemia, hyperglycemia and insulin resistance for 
disease management correction of this disorder is 
beneficial. 
Vitamin E, pioglitazone (for NAFLD/NASH with 
diabetes), statins (for NAFLD/NASH with 
dyslipidemia) are recommended therapeutic agents by 
the Japan Society of Gastroenterology (JSG) and Japan 
Society of Hepatology (JSH) [88]. And American 
Association for Study of Liver Disease (AASLD) has 
also included these substances. Vitamin E  is very 
beneficial as it scavenges the free radicals to reduce 
oxidative stress in NAFLD/NASH livers. It 
significantly improved the NASH histology in non- 
diabetic & non-cirrhotic adult NASH patients 
compared to placebo [89]. 
Vitamin E treatment has not been confirmed on the 
safety of long term & its high dose. Insulin resistance, 
steatosis, lobular inflammation and fibrosis in 
diabetic/pre-diabetic NASH patients are attenuated by 
the PPAR-g activator, pioglitazone which increases 
circulating adiponectin (clinicaltrials.gov identifier: 
NCT00994682) [90].HCC prevalence in diabetic 
patients also reduced by the PPAR- agonist, but it also 
causes some adverse effects like fluid retention 
(edema, heart failure) and osteoporosis. For 
pharmacological agents, it is the constant challenges to 
minimize the adverse effect with benefits and risks 
along with improvements. 
Novel agents under clinical trials 
Some of the trials are undergoing clinical trials, among 
them, obeticholic acid, elafibranor, selonsertib, and 
cenicriviroc are phase 3rd trials [91]. These trials 
evaluate not only histological improvement of NASH 
but also helpful in the prevention of progression into 
cirrhosis, hepatic decompensation and death. 
Obeticholic acid is a potent whole body Farnesoid X 
Receptor (FXR) agonist [92].  This significantly 
increases blood triglyceride and low-density 
lipoprotein cholesterol levels and decreases high-
density–lipoprotein-cholesterol concentrations which 
havethe chance for the risk of cardiovascular diseases. 
Elafibranor (GFT-505) acts as a dual agonist for 
PPAR-α/δ. PPARα activation attenuates hepatic 
steatosis and inflammation. While that of PPAR-α 
stimulation ameliorates hepatic inflammation and 
fibrosis [92]. Selonsertib (GS-4997) is very important 
apoptosis signal-regulating kinase 1 (ASK1) 
inhibitor.ASK1 is activated through stimulus like 
hyperglycemia, transforming growth factor β and 
oxidative stimulus that induces apoptosis and fibrosis 
by p38 and JNK. Upregulation of ASK1-JNK1 
resulting insulin resistance, steatosis, and inflammation 
and further activation of ASK1, resulting in a vicious 
cycle. 
ASK1 inhibition reduces body weight along with 
hepatic fat and fibrosisand improves insulin resistance 
in an animal NASH model [93]. In the phase 2 study, 
selonsertib makes better the NASH activity and 
fibrosis[94]. For stage 3 fibrosis and cirrhotic patient, 
an international phase 3rd trial is on working. 
(STELLAR 3 study, NCT03053050) and STELLAR4 
study, NCT03053063, respectively. Ultimately 
cenicriviroc, the antagonist for C-C motif Chemokine 
Receptor (CCR) 2/5. Currently, a NASH patient with 
stage 2/3 fibrosis is underway for phase 3 clinical trial 
of effect of cenicriviroc evaluation (Table 3)[95-99]. 
Conclusion 
NAFLD consists of hepatic disorders share common 
features, that includes hepatic fat infiltration from the 
histological point of view while from the pathogenic 
point of view IR is the feature that affects NAFLD. The 
spread of NAFLD is increasing at an alarming rate, and 
it is the most frequent hepatocyte nowadays. In the past 
few years, the information that has been accumulated 
has led to the identification of targets for therapeutics. 
Recently, the trends in diet and nowadays’ lifestyle 
increased the prevalence of NAFLD  worldwide. Some 
work is needed to checkup individuals with low 
fibrosis stage and at the risk of disease progression. 
New line drugs should be optimized for maximum 
benefit and few of the adverse events. 
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